growing in Hou

A Louisiana-born, Houston-backed outdoors activity startup is expanding into the Bayou City

Mallard Bay, which won big at the Rice Business Plan Competition, is expanding in Houston. Photo via Getty Images

A Louisiana-founded hunting and fishing startup is growing its operations and expanding into Houston.

Mallard Bay, a marketplace for booking guided fishing and hunting trips, will move half of its employees to Houston and will join the Greater Houston Partnership, according to a release from the GHP. The company hopes the move will help it tap into the large corporate and convention entertainment market in Texas.

The company was founded in 2021 by a group of Louisiana State University students after noticing a gap in the outdoor travel space. Last year, founders Logan Meaux, Joel Moreau, Wyatt Mallett and Tam Nguyen entered in the Rice Business Plan Competition and won the fourth-most in investments and prizes, totaling $218,000.

“Entering the Rice Business Plan Competition helped close out our $1.8 million seed round last September,” Meaux, co-founder and CEO of Mallard Bay, says in a statement. “Not only did it help us raise money, but the recognition and the contacts we made were instrumental in growing the business and sparked the idea to expand to Houston. Prior to the competition, we were unaware of all that the Houston startup ecosystem had to offer, but quickly realized the value of having a network here in Houston.”

That same year the company also acquired Texas-based marketing firm, Bourbon Media. The company also recently launched GuideTech, which provides guides and charter services with tools like calendar management and payment solutions for back-office use, the Baton Rouge Business Report reported earlier this year.

According to the GHP, Mallard Bay now works with more than 300 outfitters, ranchers and charter captains. The company has seen more than 1,000 percent YOY growth over the last five months.

Houston-based technology services development company Softeq Venture Studio is a major investor in Mallard Bay. According to a statement from Billy Grandy, chief innovation officer at Softeq and Managing Partner of the Softeq Venture Fund, the company began working with Mallard Bay in 2022.

"The company has garnered significant interest since participating in The Softeq Venture Studio, our hands-on startup accelerator program and we are eager to see where this next chapter takes them," Grandy added in the statement.

Softeq announced its latest cohort for its accelerator program in May.

Houston is also home to outdoors and sporting equipment marketplace Everest. Founder and CEO Bill Voss spoke on the Houston Innovators Podcast about how Everest aims to disrupt the marketplace with its seller-friendly platform.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted